The role of PET scanning in pancreatic cancer

Advances in Surgery

Volumn 44, Issue 1, 2010, Pages 313-325

  Serrano, Oscar K ^a   Chaudhry, Muhammad A ^a   Leach, Steven D ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ENDOSCOPIC ECHOGRAPHY; HUMAN; PANCREAS CARCINOMA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW; SCINTISCANNING; CARCINOMA, PANCREATIC DUCTAL; DIAGNOSTIC USE; PANCREATIC NEOPLASMS;

CARCINOMA, PANCREATIC DUCTAL; ENDOSONOGRAPHY; FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 77956151201     PISSN: 00653411     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.yasu.2010.05.007     Document Type: Review

References (42)

1. Greenlee R.T., Murray T., Bolden S., et al. Cancer statistics, 2000. CA Cancer J Clin 2000, 50:7.
2. Nieto J., Grossbard M.L., Kozuch P. Metastatic pancreatic cancer 2008: is the glass less empty?. Oncologist 2008, 13(5):562-576.
3. SEER Cancer statistics review 1973-1997, Table XXI-4 1999, National Cancer Institute, Bethesda (MD). L.A.G. Ries, C.L. Kosary, B.F. Hankey (Eds.).
4. Li D., Xie K., Wolff R., et al. Pancreatic cancer. Lancet 2004, 363(9414):1049-1057.
5. Minniti S., Bruno C., Biasiutti C., et al. Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma. J Clin Ultrasound 2003, 31(4):175-182.
6. Clarke D.L., Thomson S.R., Madiba T.E., et al. Preoperative imaging of pancreatic cancer: a management-oriented approach. J Am Coll Surg 2003, 196(1):119-129.
7. Haycox A., Lombard M., Neoptolemos J., et al. Review article: current practice and future perspectives in detection and diagnosis of pancreatic cancer. Aliment Pharmacol Ther 1998, 12(10):937-948.
8. Smith S.L., Rajan P.S. Imaging of pancreatic adenocarcinoma with emphasis on multidetector CT. Clin Radiol 2004, 59(1):26-38.
9. Fuhrman G.M., Charnsangavej C., Abbruzzese J.L., et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg 1994, 167(1):104-111. [discussion: 111-3].
10. Bipat S., Phoa S.S., van Delden O.M., et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis. J Comput Assist Tomogr 2005, 29(4):438-445.
11. Mertz H.R., Sechopoulos P., Delbeke D., et al. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc 2000, 52(3):367-371.
12. Graham R.A., Bankoff M., Hediger R., et al. Fine-needle aspiration biopsy of pancreatic ductal adenocarcinoma: loss of diagnostic accuracy with small tumors. J Surg Oncol 1994, 55(2):92-94.
13. Abdel Aziz A.M., Lehman G.A. Pancreatitis after endoscopic retrograde cholangio-pancreatography. World J Gastroenterol 2007, 13(19):2655-2668.
14. Orlando L.A., Kulasingam S.L., Matchar D.B. Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 2004, 20(10):1063-1070.
15. Berberat P., Friess H., Kashiwagi M., et al. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg 1999, 23(9):882-887.
16. Gangi S., Fletcher J.G., Nathan M.A., et al. Time interval between abnormalities seen on CT and the clinical diagnosis of pancreatic cancer: retrospective review of CT scans obtained before diagnosis. AJR Am J Roentgenol 2004, 182(4):897-903.
17. Kostakoglu L., Agress H., Goldsmith S.J. Clinical role of FDG PET in evaluation of cancer patients. Radiographics 2003, 23(2):315-340.
18. 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993, 14(7):596-601.
19. 18F- fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 1994, 192(1):79-86.
20. 18F-fluorodeoxyglucose: comparison with CT and US. Radiology 1995, 195(2):345-352.
21. Kato T., Fukatsu H., Ito K., et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995, 22(1):32-39.
22. Ho C.L., Dehdashti F., Griffeth L.K., et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr 1996, 20(3):363-369.
23. 18Fluorine-fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 1997, 24(6):678-682.
24. Keogan M.T., Tyler D., Clark L., et al. Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 1998, 171(6):1565-1570.
25. Rajput A., Stellato T.A., Faulhaber P.F., et al. The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. Surgery 1998, 124(4):793-797.
26. 18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999, 86(2):194-199.
27. Delbeke D., Rose D.M., Chapman W.C., et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999, 40(11):1784-1791.
28. 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 2000, 20(2):109-116.
29. 18F-fluorodeoxyglucose: diagnostic limitations. World J Surg 2000, 24(9):1121-1129.
30. 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 2000, 89(12):2547-2554.
31. Koyama K., Okamura T., Kawabe J., et al. Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 2001, 15(3):217-224.
32. Kasperk R.K., Riesener K.P., Wilms K., et al. Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon's view. World J Surg 2001, 25(9):1134-1139.
33. 18F-FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med 2002, 27(3):197-201.
34. Kalady M.F., Clary B.M., Clark L.A., et al. Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 2002, 9(8):799-806.
35. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999, 229(5):729-737.
36. Greene F.L. TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol 2003, 21(1):23-29.
37. Delbeke D., Pinson C.W. Pancreatic tumors: role of imaging in the diagnosis, staging, and treatment. J Hepatobiliary Pancreat Surg 2004, 11(1):4-10.
38. Fröhlich A., Diederichs C.G., Staib L., et al. Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 1999, 40(2):250-255.
39. Gambhir S.S., Czernin J., Schwimmer J., et al. A tabulated summary of the FDG PET literature. J Nucl Med 2001, 42(Suppl 5):1S-93S.
40. Ruf J., Lopez Hänninen E., Oettle H., et al. Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 2005, 5(2-3):266-272.
41. 18F-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J Nucl Med 2004, 45(8):1279-1286.
42. Heinrich S., Goerres G.W., Schäfer M., et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005, 242(2):235-243.